CN104910269B - A method of synthesis Teriparatide - Google Patents
A method of synthesis Teriparatide Download PDFInfo
- Publication number
- CN104910269B CN104910269B CN201510295556.2A CN201510295556A CN104910269B CN 104910269 B CN104910269 B CN 104910269B CN 201510295556 A CN201510295556 A CN 201510295556A CN 104910269 B CN104910269 B CN 104910269B
- Authority
- CN
- China
- Prior art keywords
- teriparatide
- coupling
- resin
- purifying
- obtains
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 108010049264 Teriparatide Proteins 0.000 title claims abstract description 75
- 229960005460 teriparatide Drugs 0.000 title claims abstract description 66
- OGBMKVWORPGQRR-UMXFMPSGSA-N teriparatide Chemical compound C([C@H](NC(=O)[C@H](CCSC)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@@H](N)CO)C(C)C)[C@@H](C)CC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC=1N=CNC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1N=CNC=1)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)C1=CNC=N1 OGBMKVWORPGQRR-UMXFMPSGSA-N 0.000 title claims abstract description 61
- 238000000034 method Methods 0.000 title claims abstract description 37
- 230000015572 biosynthetic process Effects 0.000 title claims abstract description 26
- 238000003786 synthesis reaction Methods 0.000 title claims abstract description 25
- 229920005989 resin Polymers 0.000 claims abstract description 94
- 239000011347 resin Substances 0.000 claims abstract description 93
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 39
- 238000005859 coupling reaction Methods 0.000 claims abstract description 30
- 150000001413 amino acids Chemical class 0.000 claims abstract description 27
- 239000003153 chemical reaction reagent Substances 0.000 claims abstract description 26
- 230000008878 coupling Effects 0.000 claims abstract description 26
- 238000010168 coupling process Methods 0.000 claims abstract description 26
- 239000012043 crude product Substances 0.000 claims abstract description 22
- 125000006239 protecting group Chemical group 0.000 claims abstract description 21
- 238000009833 condensation Methods 0.000 claims abstract description 10
- 230000005494 condensation Effects 0.000 claims abstract description 10
- 230000003213 activating effect Effects 0.000 claims abstract description 8
- 230000000694 effects Effects 0.000 claims abstract description 7
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 claims abstract description 5
- 210000004899 c-terminal region Anatomy 0.000 claims abstract description 5
- 230000032050 esterification Effects 0.000 claims abstract description 4
- 238000005886 esterification reaction Methods 0.000 claims abstract description 4
- 239000000243 solution Substances 0.000 claims description 40
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 claims description 35
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims description 30
- 238000010828 elution Methods 0.000 claims description 20
- 150000007530 organic bases Chemical class 0.000 claims description 20
- 150000003839 salts Chemical class 0.000 claims description 15
- 238000001914 filtration Methods 0.000 claims description 14
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 14
- BDNKZNFMNDZQMI-UHFFFAOYSA-N 1,3-diisopropylcarbodiimide Chemical compound CC(C)N=C=NC(C)C BDNKZNFMNDZQMI-UHFFFAOYSA-N 0.000 claims description 11
- 150000001408 amides Chemical class 0.000 claims description 11
- 238000004128 high performance liquid chromatography Methods 0.000 claims description 11
- 238000005903 acid hydrolysis reaction Methods 0.000 claims description 10
- 239000012141 concentrate Substances 0.000 claims description 10
- -1 hexafluorophosphoric acid benzotriazole Chemical compound 0.000 claims description 10
- 238000002156 mixing Methods 0.000 claims description 10
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 claims description 9
- 229910052757 nitrogen Inorganic materials 0.000 claims description 9
- NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Substances O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 claims description 7
- 239000000463 material Substances 0.000 claims description 6
- 238000012856 packing Methods 0.000 claims description 6
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 claims description 5
- 239000007864 aqueous solution Substances 0.000 claims description 5
- 239000012528 membrane Substances 0.000 claims description 5
- 239000012982 microporous membrane Substances 0.000 claims description 5
- 230000009977 dual effect Effects 0.000 claims description 3
- SJRJJKPEHAURKC-UHFFFAOYSA-N N-Methylmorpholine Chemical class CN1CCOCC1 SJRJJKPEHAURKC-UHFFFAOYSA-N 0.000 claims description 2
- 229910052698 phosphorus Inorganic materials 0.000 claims description 2
- 239000011574 phosphorus Substances 0.000 claims description 2
- 230000004913 activation Effects 0.000 claims 1
- QRUDEWIWKLJBPS-UHFFFAOYSA-N benzotriazole Chemical compound C1=CC=C2N[N][N]C2=C1 QRUDEWIWKLJBPS-UHFFFAOYSA-N 0.000 claims 1
- 238000001514 detection method Methods 0.000 claims 1
- 239000007788 liquid Substances 0.000 claims 1
- 238000011084 recovery Methods 0.000 abstract description 17
- 238000005516 engineering process Methods 0.000 abstract description 5
- 239000000047 product Substances 0.000 abstract description 5
- 231100001261 hazardous Toxicity 0.000 abstract description 2
- 239000012071 phase Substances 0.000 description 25
- 235000001014 amino acid Nutrition 0.000 description 21
- 229940024606 amino acid Drugs 0.000 description 21
- 238000006243 chemical reaction Methods 0.000 description 13
- 238000005406 washing Methods 0.000 description 12
- 238000006467 substitution reaction Methods 0.000 description 11
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 10
- 125000004213 tert-butoxy group Chemical group [H]C([H])([H])C(O*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 10
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 9
- BGRWYRAHAFMIBJ-UHFFFAOYSA-N diisopropylcarbodiimide Natural products CC(C)NC(=O)NC(C)C BGRWYRAHAFMIBJ-UHFFFAOYSA-N 0.000 description 9
- 238000003756 stirring Methods 0.000 description 9
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 7
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 6
- 239000000706 filtrate Substances 0.000 description 6
- 239000000203 mixture Substances 0.000 description 6
- 238000001556 precipitation Methods 0.000 description 6
- 238000002360 preparation method Methods 0.000 description 5
- 239000007790 solid phase Substances 0.000 description 5
- SJVFAHZPLIXNDH-QFIPXVFZSA-N (2s)-2-(9h-fluoren-9-ylmethoxycarbonylamino)-3-phenylpropanoic acid Chemical compound C([C@@H](C(=O)O)NC(=O)OCC1C2=CC=CC=C2C2=CC=CC=C21)C1=CC=CC=C1 SJVFAHZPLIXNDH-QFIPXVFZSA-N 0.000 description 4
- 125000003088 (fluoren-9-ylmethoxy)carbonyl group Chemical group 0.000 description 4
- 229960000549 4-dimethylaminophenol Drugs 0.000 description 4
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 4
- 239000007821 HATU Substances 0.000 description 4
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 4
- 108090000445 Parathyroid hormone Proteins 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 238000004587 chromatography analysis Methods 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 239000000945 filler Substances 0.000 description 4
- 239000007791 liquid phase Substances 0.000 description 4
- JFLSOKIMYBSASW-UHFFFAOYSA-N 1-chloro-2-[chloro(diphenyl)methyl]benzene Chemical compound ClC1=CC=CC=C1C(Cl)(C=1C=CC=CC=1)C1=CC=CC=C1 JFLSOKIMYBSASW-UHFFFAOYSA-N 0.000 description 3
- 102100036893 Parathyroid hormone Human genes 0.000 description 3
- 239000012317 TBTU Substances 0.000 description 3
- CLZISMQKJZCZDN-UHFFFAOYSA-N [benzotriazol-1-yloxy(dimethylamino)methylidene]-dimethylazanium Chemical compound C1=CC=C2N(OC(N(C)C)=[N+](C)C)N=NC2=C1 CLZISMQKJZCZDN-UHFFFAOYSA-N 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 238000010511 deprotection reaction Methods 0.000 description 3
- 239000012535 impurity Substances 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- FEMOMIGRRWSMCU-UHFFFAOYSA-N ninhydrin Chemical compound C1=CC=C2C(=O)C(O)(O)C(=O)C2=C1 FEMOMIGRRWSMCU-UHFFFAOYSA-N 0.000 description 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 3
- 239000011541 reaction mixture Substances 0.000 description 3
- 235000004400 serine Nutrition 0.000 description 3
- 238000003746 solid phase reaction Methods 0.000 description 3
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 2
- 206010017076 Fracture Diseases 0.000 description 2
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 2
- 239000003875 Wang resin Substances 0.000 description 2
- NERFNHBZJXXFGY-UHFFFAOYSA-N [4-[(4-methylphenyl)methoxy]phenyl]methanol Chemical compound C1=CC(C)=CC=C1COC1=CC=C(CO)C=C1 NERFNHBZJXXFGY-UHFFFAOYSA-N 0.000 description 2
- 229910021529 ammonia Inorganic materials 0.000 description 2
- 235000009582 asparagine Nutrition 0.000 description 2
- 229960001230 asparagine Drugs 0.000 description 2
- 210000000988 bone and bone Anatomy 0.000 description 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 2
- 238000006482 condensation reaction Methods 0.000 description 2
- 239000011259 mixed solution Substances 0.000 description 2
- 150000003053 piperidines Chemical class 0.000 description 2
- 238000010189 synthetic method Methods 0.000 description 2
- XXMYDXUIZKNHDT-QNGWXLTQSA-N (2s)-2-(9h-fluoren-9-ylmethoxycarbonylamino)-3-(1-tritylimidazol-4-yl)propanoic acid Chemical compound C([C@@H](C(=O)O)NC(=O)OCC1C2=CC=CC=C2C2=CC=CC=C21)C(N=C1)=CN1C(C=1C=CC=CC=1)(C=1C=CC=CC=1)C1=CC=CC=C1 XXMYDXUIZKNHDT-QNGWXLTQSA-N 0.000 description 1
- REITVGIIZHFVGU-IBGZPJMESA-N (2s)-2-(9h-fluoren-9-ylmethoxycarbonylamino)-3-[(2-methylpropan-2-yl)oxy]propanoic acid Chemical compound C1=CC=C2C(COC(=O)N[C@@H](COC(C)(C)C)C(O)=O)C3=CC=CC=C3C2=C1 REITVGIIZHFVGU-IBGZPJMESA-N 0.000 description 1
- ADOHASQZJSJZBT-SANMLTNESA-N (2s)-2-(9h-fluoren-9-ylmethoxycarbonylamino)-3-[1-[(2-methylpropan-2-yl)oxycarbonyl]indol-3-yl]propanoic acid Chemical compound C12=CC=CC=C2N(C(=O)OC(C)(C)C)C=C1C[C@@H](C(O)=O)NC(=O)OCC1C2=CC=CC=C2C2=CC=CC=C21 ADOHASQZJSJZBT-SANMLTNESA-N 0.000 description 1
- FODJWPHPWBKDON-IBGZPJMESA-N (2s)-2-(9h-fluoren-9-ylmethoxycarbonylamino)-4-[(2-methylpropan-2-yl)oxy]-4-oxobutanoic acid Chemical compound C1=CC=C2C(COC(=O)N[C@@H](CC(=O)OC(C)(C)C)C(O)=O)C3=CC=CC=C3C2=C1 FODJWPHPWBKDON-IBGZPJMESA-N 0.000 description 1
- CBPJQFCAFFNICX-IBGZPJMESA-N (2s)-2-(9h-fluoren-9-ylmethoxycarbonylamino)-4-methylpentanoic acid Chemical compound C1=CC=C2C(COC(=O)N[C@@H](CC(C)C)C(O)=O)C3=CC=CC=C3C2=C1 CBPJQFCAFFNICX-IBGZPJMESA-N 0.000 description 1
- BUBGAUHBELNDEW-SFHVURJKSA-N (2s)-2-(9h-fluoren-9-ylmethoxycarbonylamino)-4-methylsulfanylbutanoic acid Chemical compound C1=CC=C2C(COC(=O)N[C@@H](CCSC)C(O)=O)C3=CC=CC=C3C2=C1 BUBGAUHBELNDEW-SFHVURJKSA-N 0.000 description 1
- KJYAFJQCGPUXJY-UMSFTDKQSA-N (2s)-2-(9h-fluoren-9-ylmethoxycarbonylamino)-4-oxo-4-(tritylamino)butanoic acid Chemical compound C([C@@H](C(=O)O)NC(=O)OCC1C2=CC=CC=C2C2=CC=CC=C21)C(=O)NC(C=1C=CC=CC=1)(C=1C=CC=CC=1)C1=CC=CC=C1 KJYAFJQCGPUXJY-UMSFTDKQSA-N 0.000 description 1
- OTKXCALUHMPIGM-FQEVSTJZSA-N (2s)-2-(9h-fluoren-9-ylmethoxycarbonylamino)-5-[(2-methylpropan-2-yl)oxy]-5-oxopentanoic acid Chemical compound C1=CC=C2C(COC(=O)N[C@@H](CCC(=O)OC(C)(C)C)C(O)=O)C3=CC=CC=C3C2=C1 OTKXCALUHMPIGM-FQEVSTJZSA-N 0.000 description 1
- WDGICUODAOGOMO-DHUJRADRSA-N (2s)-2-(9h-fluoren-9-ylmethoxycarbonylamino)-5-oxo-5-(tritylamino)pentanoic acid Chemical compound C([C@@H](C(=O)O)NC(=O)OCC1C2=CC=CC=C2C2=CC=CC=C21)CC(=O)NC(C=1C=CC=CC=1)(C=1C=CC=CC=1)C1=CC=CC=C1 WDGICUODAOGOMO-DHUJRADRSA-N 0.000 description 1
- UMRUUWFGLGNQLI-QFIPXVFZSA-N (2s)-2-(9h-fluoren-9-ylmethoxycarbonylamino)-6-[(2-methylpropan-2-yl)oxycarbonylamino]hexanoic acid Chemical compound C1=CC=C2C(COC(=O)N[C@@H](CCCCNC(=O)OC(C)(C)C)C(O)=O)C3=CC=CC=C3C2=C1 UMRUUWFGLGNQLI-QFIPXVFZSA-N 0.000 description 1
- CVFXPOKENLGCID-KRWDZBQOSA-N (2s)-5-[[amino-[(2,2,4,6,7-pentamethyl-3h-1-benzofuran-5-yl)sulfonylamino]methylidene]amino]-2-[(2-methylpropan-2-yl)oxycarbonylamino]pentanoic acid Chemical compound CC1=C(S(=O)(=O)NC(N)=NCCC[C@H](NC(=O)OC(C)(C)C)C(O)=O)C(C)=C2CC(C)(C)OC2=C1C CVFXPOKENLGCID-KRWDZBQOSA-N 0.000 description 1
- QXVFEIPAZSXRGM-DJJJIMSYSA-N (2s,3s)-2-(9h-fluoren-9-ylmethoxycarbonylamino)-3-methylpentanoic acid Chemical compound C1=CC=C2C(COC(=O)N[C@@H]([C@@H](C)CC)C(O)=O)C3=CC=CC=C3C2=C1 QXVFEIPAZSXRGM-DJJJIMSYSA-N 0.000 description 1
- NDKDFTQNXLHCGO-UHFFFAOYSA-N 2-(9h-fluoren-9-ylmethoxycarbonylamino)acetic acid Chemical compound C1=CC=C2C(COC(=O)NCC(=O)O)C3=CC=CC=C3C2=C1 NDKDFTQNXLHCGO-UHFFFAOYSA-N 0.000 description 1
- 206010065687 Bone loss Diseases 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- OBMZMSLWNNWEJA-XNCRXQDQSA-N C1=CC=2C(C[C@@H]3NC(=O)[C@@H](NC(=O)[C@H](NC(=O)N(CC#CCN(CCCC[C@H](NC(=O)[C@@H](CC4=CC=CC=C4)NC3=O)C(=O)N)CC=C)NC(=O)[C@@H](N)C)CC3=CNC4=C3C=CC=C4)C)=CNC=2C=C1 Chemical group C1=CC=2C(C[C@@H]3NC(=O)[C@@H](NC(=O)[C@H](NC(=O)N(CC#CCN(CCCC[C@H](NC(=O)[C@@H](CC4=CC=CC=C4)NC3=O)C(=O)N)CC=C)NC(=O)[C@@H](N)C)CC3=CNC4=C3C=CC=C4)C)=CNC=2C=C1 OBMZMSLWNNWEJA-XNCRXQDQSA-N 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 108010016626 Dipeptides Proteins 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 101001135770 Homo sapiens Parathyroid hormone Proteins 0.000 description 1
- 101001135995 Homo sapiens Probable peptidyl-tRNA hydrolase Proteins 0.000 description 1
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 208000001132 Osteoporosis Diseases 0.000 description 1
- 102000003982 Parathyroid hormone Human genes 0.000 description 1
- 101710176384 Peptide 1 Proteins 0.000 description 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 229920003180 amino resin Polymers 0.000 description 1
- 125000005605 benzo group Chemical group 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 210000001217 buttock Anatomy 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 150000002466 imines Chemical class 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 210000004897 n-terminal region Anatomy 0.000 description 1
- 210000000963 osteoblast Anatomy 0.000 description 1
- 210000002997 osteoclast Anatomy 0.000 description 1
- 230000000849 parathyroid Effects 0.000 description 1
- 239000000199 parathyroid hormone Substances 0.000 description 1
- 229960001319 parathyroid hormone Drugs 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 208000001685 postmenopausal osteoporosis Diseases 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 230000035484 reaction time Effects 0.000 description 1
- 150000003355 serines Chemical class 0.000 description 1
Classifications
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Endocrinology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Peptides Or Proteins (AREA)
- Biochemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Biophysics (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Toxicology (AREA)
Abstract
The present invention relates to medical synthesis fields, disclose a kind of method of synthesis Teriparatide.N-terminal coupling is had the Phe of protecting group under coupling reagent and activating reagent effect to the method and HMP Linker resins carry out esterification, obtains peptide resin 1；According to the sequence of Teriparatide amino acid sequence C-terminal to N-terminal; from peptide resin 1; under condensation reagent and activating reagent effect; remaining protected amino acid is carried out to extend coupling one by one; corresponding peptide resin is obtained after extending coupling every time; final to obtain Teriparatide resin, then acidolysis obtains Teriparatide crude product, and Teriparatide purifying crude turns acetate and obtains Teriparatide sterling.The present invention selects suitable synthetic schemes, selects HMP Linker resins as vector resin, and optimize entire synthesis technology, obtains high purity product, improves the total recovery of Teriparatide, and non-hazardous to any environment.
Description
Technical field
The present invention relates to medical synthesis fields, and in particular to a method of synthesis Teriparatide.
Background technology
Teriparatide is a kind of 34 peptides of synthesis, is the 1-34 amino acid fragments of human parathyroid hormone PTH, amino acid sequence
It is as follows：
H-Ser1-Val2-Ser3-Glu4-Ile5-Gln6-Leu7-Met8-His9-Asn10-Leu11-Gly12-Lys13-
His14-Leu15-Asn16-Ser17-Met18-Glu19-Arg20-Val21-Glu22-Trp23-Leu24-Arg25-Lys26-Lys27-
Leu28-Gln29-Asp30-Val31-His32-Asn33-Phe34-OH
The segment is the biologically active N- terminal regions of endogenous parathormone PTH containing 84 amino acid.
The immunology and biological characteristics and endogenous parathormone PTH and bovine parathyroid element PTH (bPTH) complete phase of this product
Together.
Teriparatide is that the first obtains U.S.'s food and the bon e formation agent kind new medicine of Drug Administration FDA approvals, this
The derivative of parathyroid hormone can promote bone uptake by increasing the activity and quantity of osteoblast, and current routine
Medicine for treating osteoporosis typically just acts on osteoclast and slows down or block bone-loss, and Teriparatide is given birth to come pharmaceutical factory by gift
Production, the clinical study results for being related to 1637 patients with postmenopausal osteoporosis are shown, calcium and dimension have only been taken with those
The patient of raw element D additives compares, and 96% patient is after receiving medicine treatment, bone (minerals) density of backbone and buttocks
BMD shows to dramatically increase, it is moreover found that the medicine can be reduced respectively occurs spine fracture and other types risk of fractures
65% and 53%.
For method prepared by this product, existing patented technology carries out disclosure.Chinese patent CN102731643A disclose with
2- chlorine trityl chloride resin (2-CTC resins) is that 5 segments of solid phase carrier flavor are coupled, although this method can shorten
Synthesis cycle, but its total recovery is only up to 32.2%.
Instantly popular synthetic method is solid phase Stepwise synthesis (SPPS), and this method has easy to operate and equipment
It is required that low advantage, but this method also limits the production efficiency of Teriparatide because total recovery is relatively low.Such as patent
CN103467595A, when gradually synthesis of coupling is to 17 serines, with unprotected serine and 16 asparagine carboxylics
Base carries out ester condensation, converts ester bond to amido bond again after obtaining thick peptide, total recovery is up to 42.1%.Patent
CN104017064A also discloses that a kind of gradually synthetic method, used when synthesize 16-17 amino acids pseudo proline dipeptides,
And cracked with specific lysate, total recovery is up to 38%.Patent CN104530218A discloses a kind of gradually synthesis side
Method is synthesized using Wang resin or 2-CTC resins as solid phase carrier, total recovery 34.72%.
In summary from the point of view of the synthetic schemes of existing Teriparatide, total recovery is not high, and highest is 42.1%, though
Right CN103467595A claims its total recovery between 30-50% wherein, but according to the detailed record of embodiment, highest is only
It is 42.1%.Lower total recovery is to limit the principal element of Teriparatide production efficiency, needs to be improved existing synthetic schemes
To improve its total recovery.
Invention content
In view of this, the purpose of the present invention is to provide a kind of preparation methods of Teriparatide so that side of the present invention
Method improves the total recovery of Teriparatide under the premise of ensureing higher purity.
To achieve the above object, the present invention provides the following technical solutions：
A method of synthesis Teriparatide includes the following steps：
Step 1, N-terminal coupling have the Phe of protecting group under coupling reagent and activating reagent effect and HMP Linker resins
Esterification is carried out, peptide resin 1 is obtained；
Step 2, according to the sequence of Teriparatide amino acid sequence C-terminal to N-terminal, from peptide resin 1, in condensation reagent and
Under activating reagent effect, remaining protected amino acid is carried out to extend coupling one by one, corresponding peptide is obtained after extending coupling every time
Resin, final to obtain Teriparatide resin, then acidolysis obtains Teriparatide crude product, and Teriparatide purifying crude turns acetate and obtains
To Teriparatide sterling.
Teriparatide backbone amino acid has 34, and composition is as follows：
H-Ser1-Val2-Ser3-Glu4-Ile5-Gln6-Leu7-Met8-His9-Asn10-Leu11-Gly12-Lys13-
His14-Leu15-Asn16-Ser17-Met18-Glu19-Arg20-Val21-Glu22-Trp23-Leu24-Arg25-Lys26-Lys27-
Leu28-Gln29-Asp30-Val31-His32-Asn33-Phe34-OH
The present invention is solid phase carrier for Wang resin or 2-CTC resins is all made of in the prior art, causes Teriparatide total
The lower defect of yield selects HMP Linker resins to carry out the gradually synthesis of Teriparatide as solid phase carrier, is ensureing spy
Its total recovery is improved under the premise of vertical pa peptide purity.
Protecting group of the present invention be on the common protected amino acid main chain in Amino acid synthesis field and side chain amino,
The blocking group of the group of the interference such as carboxyl synthesis, prevents amino, carboxyl etc. from reacting during preparing target product, raw
At impurity, for the amino acid for needing to protect side chain in the present invention, its side-chain structure well known to those skilled in the art and
Know using commonly using protecting group come groups such as amino, carboxyls on protected amino acid side chain, preferably, the present invention passes through tBu
Protecting group protects the side chain of serine；Arginic side chain is protected by Pdf protecting groups；Pass through OtBu protecting group protection door winter ammonia
The side chain of acid, glutamic acid；The side chain of histidine, asparagine, glutamine is protected by Trt protecting groups；It is protected by Boc protecting groups
Protect the side chain of lysine, tryptophan.In addition, in the protected amino acid that the method for the invention is related to, N-terminal preferably passes through
Fmoc protecting groups are protected.Protected amino acid is known as by the amino acid that protecting group is protected.Preferably, remaining described protection ammonia
Base acid be Boc-Arg (Pbf)-OH, Fmoc-Asp (OtBu)-OH, Fmoc-Asn (Trt)-OH, Fmoc-Gln (Trt)-OH,
Fmoc-Glu(OtBu)-OH、Fmoc-Gly-OH、Fmoc-His(Trt)-OH、Fmoc-Ile-OH、Fmoc-Leu-OH、Fmoc-
Lys(Boc)-OH、Fmoc-Met-OH、Fmoc-Phe-OH、Fmoc-Ser(tBu)-OH、Fmoc-Trp(Boc)-OH、Fmoc-
Val-OH。
Preferably, protecting group described in step 1 is Fomc protecting groups.
Preferably, the HMP Linker resins are HMP Linker Amide resins, HMP Linker bha resins
Or HMP Linker MBHA resins.Each resin structure is following (P represents representation polymer)：
Preferably, it is 1-6 that the N-terminal coupling, which has the molar ratio of the Phe and HMP Linker resins of protecting group,:1, it is more excellent
It is selected as 2.5-3.5:1.
Preferably, the substitution value of the peptide resin 1 is 0.2-1.0mmol/g peptide resins 1, more preferably 0.3-
0.6mmol/g peptide resins 1.
Preferably, the condensation reagent is preferably N, and N- diisopropylcarbodiimide (DIC), N, N- dicyclohexyls carbon two
Imines (DCC), hexafluorophosphoric acid benzotriazole -1- bases-oxygroup tripyrrole alkyl phosphorus/organic base (PyBOP/ organic bases), 2- (7- nitrogen
Miscellaneous -1H- benzotriazole -1- bases) -1,1,3,3- tetramethylureas hexafluorophosphoric acid ester/organic base (HATU/ organic bases), benzo three
Nitrogen azoles-N, N, N', N'- tetramethylurea hexafluorophosphate/organic base (HBTU/ organic bases), O- benzotriazole-N, N, N', N'-
One kind in tetramethylurea tetrafluoro boric acid ester/organic base (TBTU/ organic bases).The mole dosage of the condensation reagent is preferably peptide
1~6 times of molal quantity, more preferably 2.5~3.5 times in resin.
It should be noted that the PyBOP/ organic bases, HATU/ organic bases, HBTU/ organic bases, TBTU/ organic bases,
Belong to the condensation reagent of four kinds of Dual systems in the present invention, i.e., PyBOP, HATU, HBTU need when in use respectively with organic base group
It is used together into a kind of condensation reagent, wherein the molar ratio of the organic base and PyBOP, HATU, HBTU, TBTU are preferred
For for 1.3-3.0:1, more preferably 1.3-2:1.
Preferably, the organic base in the condensation reagent is preferably n,N-diisopropylethylamine (DIPEA), triethylamine
(TEA) or N- methylmorpholines (NMM), more preferably DIPEA.
Preferably, the activating reagent is I-hydroxybenzotriazole (HOBt) or N- hydroxyl -7- azepine benzotriazole
(HOAt).The dosage of the activating reagent is preferably 1~6 times of molal quantity in peptide resin, more preferably 2.5~3.5 times.
Preferably, the coupling reagent is N, N- diisopropylcarbodiimide/4-dimethylaminopyridine (DIC/DMAP)
Dual system coupling reagent.
Preferably, the esterification and the reaction dissolvent of extension coupling are all made of DMF.
Extension coupling of the present invention refers to after first amino acid and amino resins coupling, and remaining amino acid is according to spy
With the amino acid of previous coupling condensation reaction (backbone amino and carboxylic occur for the sequence of the C-terminal of vertical pa peptide ammino acid to N-terminal one by one
The condensation reaction of base) it is coupled.When the present invention is coupled, extend the protected amino acid and corresponding peptide resin when coupling every time
Molar ratio is preferably 1-6:1, more preferably 2.5-3.5:1；The coupling reaction time is preferably 60~300 minutes, more preferably
It is 100~140 minutes.The corresponding peptide resin refers to according to the sequence of Teriparatide amino acid sequence C-terminal to N-terminal, from peptide
Resin 1 sets out, each protected amino acid needs the peptide resin being coupled when being gradually coupled.
In extending coupling, since there is protecting group at each amino acid N end, it is therefore desirable to it is even again first to remove N-terminal protecting group
Connection, this is common knowledge for a person skilled in the art.The present invention preferably uses PIP/DMF (piperidines/N, N- dimethyl formyls
Amine) mixed solution removes N-terminal protecting group, and containing piperidines it is 10~30% (V) in mixed solution, remaining is DMF.Go N-terminal protecting group
Time is preferably 10~60 minutes, preferably 15~25 minutes.Go the dosage of N-terminal protecting group reagent preferably per 0.05mol
Peptide resin 1000-1600mL.
It should be noted that peptide resin of the present invention refer to any number amino acid according to Teriparatide amino acid sequence and
HMP Linker resins are connected the peptide resin to be formed, and also include peptide resin 1 among these.
Preferably, it is 1-10%'s for the TFA of 80-95%, percent by volume that the acidolysis, which is used by percent by volume,
EDT, the mixing acid hydrolysis solution acidolysis that surplus is water composition.It is highly preferred that the acidolysis is used by percent by volume as 90%
EDT that TFA, percent by volume are 5%, surplus are the mixing acid hydrolysis solution acidolysis of water composition.The mixing acid hydrolysis solution dosage is preferred
Pa peptide resin, which is found, for every cut needs 4~15mL, more preferably 9~11mL.The time of the acidolysis preferably under room temperature 1
~6 hours, more preferably 3~4 hours.
Preferably, the purifying turns acetate step and is specially：
Teriparatide crude product adds 10% acetum to dissolve, 0.45 μm of filtering with microporous membrane of solution, and purifying is spare；
It is purified using high performance liquid chromatography, the reverse phase C18 that purifying chromatograph packing material is 10 μm, flow phase system is
The column flow rate of 0.1%TFA/ aqueous solution -0.1%TFA/ acetonitrile solutions, 77mm*250mm is 90mL/min, using gradient system
System elution, cycle sample introduction purifying, takes crude product solution to be splined in chromatographic column, starts mobile phase elution, collects main peak and boils off acetonitrile
Afterwards, Teriparatide purifying intermediate concentrate is obtained；
It takes Teriparatide to purify intermediate concentrate, is filtered with 0.45 μm of filter membrane spare；
It carries out changing salt using high performance liquid chromatography, flow phase system is 1% acetic acid/water solution-acetonitrile, purifying chromatography
The column flow rate for the reverse phase C18,77mm*250mm that filler is 10 μm is 90mL/min, using gradient elution, sample prescription in cycle
Method is splined in chromatographic column, is started mobile phase elution, is acquired collection of illustrative plates, observe the variation of trap, and collection changes salt main peak and with dividing
It analyses liquid phase and detects purity, salt main peak solution is changed in merging, is concentrated under reduced pressure, obtains Teriparatide aqueous acetic acid, is freeze-dried, obtains special
Vertical pa peptide sterling.
It is detected through HPLC by the Teriparatide that the method for the invention synthesizes, purity highest is more than 99%, and maximum is single miscellaneous
Matter is less than 0.15%, and total recovery is more than 47%, far above the yield disclosed in the prior art.
By above technical scheme it is found that the present invention selects suitable synthetic schemes, select HMP Linker resins as load
Body resin, and entire synthesis technology is optimized, high purity product is obtained, improves the total recovery of Teriparatide, and to appointing
What environment is non-hazardous.
Specific implementation mode
The invention discloses a kind of method of synthesis Teriparatide, those skilled in the art can use for reference present disclosure, fit
When modified technique parameter is realized.In particular, it should be pointed out that all similar substitutions and modifications are for a person skilled in the art
It is it will be apparent that they are considered as being included in the present invention.The method of the present invention is retouched by preferred embodiment
State, related personnel obviously can not depart from the content of present invention, in spirit and scope to compound as described herein and preparation side
Method is modified or suitably changes and combines, to realize and apply the technology of the present invention.
In the specific embodiment of the invention, the amino acid in the present invention is purchased from the limited public affairs of Chengdu sunshine Rong's biotechnology
Department, resin used are purchased from Shangyu Poole resin Co., Ltd, and the corresponding Chinese meaning of english abbreviation used is shown in application documents
Table 1.
1 english abbreviation paraphrase of table
With reference to embodiment, the present invention is further explained.
Embodiment 1：The synthesis of peptide resin 1
By the HMP Linker Amide resins that 200g substitution values are 0.65mmol/g, it is added in solid phase reaction column, adds
It is drained after entering DMF swellable resins 30 minutes.100.6g Fmoc-Phe-OH and 35.1g HOBt are taken, is dissolved, is added to DMF
It states in resin, 35mL DIC and 3.2g DMAP is added after stirring evenly, reaction 6 hours is stirred at room temperature, takes out reaction solution, DMF
After washing 3 times, DCM is washed 3 times, and methanol washs 3 times, and each wash time is 3min, obtains Fmoc-Phe-HMP Linker
Amide resins, substitution value 0.50mmol/g.
Embodiment 2：The synthesis of peptide resin 1
It is added to the HMP Linker bha resins that 200g substitution values are 0.6mmol/g in solid phase reaction column, is added
DMF swellable resins are drained after 30 minutes.92.9g Fmoc-Phe-OH and 32.4g HOBt are taken, are dissolved with DMF, are added to above-mentioned
In resin, 32mL DIC and 2.9g DMAP are added after stirring evenly, and reaction 6 hours is stirred at room temperature, takes out reaction solution, DMF is washed
After washing 3 times, DCM is washed 3 times, and methanol washs 3 times, and each wash time is 3min, obtains Fmoc-Phe-HMP Linker BHA
Resin, substitution value 0.46mmol/g.
Embodiment 3：The synthesis of peptide resin 1
It is added to the HMP Linker MBHA resins that 200g substitution values are 0.6mmol/g in solid phase reaction column, is added
DMF swellable resins are drained after 30 minutes.92.9g Fmoc-Phe-OH and 32.4g HOBt are taken, are dissolved with DMF, are added to above-mentioned
In resin, 32mL DIC and 2.9g DMAP are added after stirring evenly, and reaction 6 hours is stirred at room temperature, takes out reaction solution, DMF is washed
After washing 3 times, DCM is washed 3 times, and methanol washs 3 times, and each wash time is 3min, obtains Fmoc-Phe-HMP Linker
MBHA resin, substitution value 0.49mmol/g.
Embodiment 4：The synthesis of Teriparatide peptide resin
The Fmoc-Phe-HMP Linker Amide resins (substitution value 0.50mmol/g) of 0.1mol embodiments 1 are taken, are used
20%PIP/DMF solution deprotects 25 minutes, and washing filtering obtains the H-Phe-HMP Linker Amide resins of Fmoc.
0.3mol Fmoc-Asn (Trt) and 0.3mol HOBt are taken, are dissolved with appropriate DMF；0.3mol DIC separately are taken, are stirred
Under be slowly added into, continue to be stirred to react 30 minutes, be added in above-mentioned H-Phe-HMP Linker Amide resins, coupling reaction
120~300 minutes, reaction end was subject to ninhydrin method and is detected, washing filtering, then with 20%PIP/DMF solution deprotection 25
Minute, washing filtering obtains H-Asn (Trt)-Phe-HMP Linker Amide resins.
Ibid method is sequentially ingressed into following table protected amino acid or segment, obtains Teriparatide peptide resin：
H-Ser(tBu)-Val-Ser(tBu)-Glu(OtBu)-Ile-Gln(Trt)-Leu-Met-His(Trt)-Asn
(Trt)-Leu-Gly-Lys(Boc)-His(Trt)-Leu-Asn(Trt)-Ser(tBu)-Met-Glu(OtBu)-Arg(Pbf)-
Val-Glu(OtBu)-Trp(Boc)-Leu-Arg(Pbf)-Lys(Boc)-Lys(Boc)-Leu-Gln(Trt)-Asp(OtBu)-
Val-His (Trt)-Asn (Trt)-Phe-HMP Linker Amide resins
Embodiment 5：The synthesis of Teriparatide peptide resin
The Fmoc-Phe-HMP Linker bha resins (substitution value 0.50mmol/g) of 0.1mol embodiments 2 are taken, are used
20%PIP/DMF solution deprotects 25 minutes, and washing filtering obtains the H-Phe-HMP Linker Amide resins of Fmoc.
0.3mol Fmoc-Asn (Trt) and 0.3mol HOBt are taken, are dissolved with appropriate DMF；0.3mol DIC separately are taken, are stirred
Under be slowly added into, continue to be stirred to react 30 minutes, be added in above-mentioned H-Phe-HMP Linker bha resins, coupling reaction
120~300 minutes, reaction end was subject to ninhydrin method and is detected, washing filtering, then with 20%PIP/DMF solution deprotection 25
Minute, washing filtering obtains Asn (Trt)-Phe-HMP Linker bha resins.
Ibid method is sequentially ingressed into following table protected amino acid or segment, obtains Teriparatide peptide resin：
H-Ser(tBu)-Val-Ser(tBu)-Glu(OtBu)-Ile-Gln(Trt)-Leu-Met-His(Trt)-Asn
(Trt)-Leu-Gly-Lys(Boc)-His(Trt)-Leu-Asn(Trt)-Ser(tBu)-Met-Glu(OtBu)-Arg(Pbf)-
Val-Glu(OtBu)-Trp(Boc)-Leu-Arg(Pbf)-Lys(Boc)-Lys(Boc)-Leu-Gln(Trt)-Asp(OtBu)-
Val-His (Trt)-Asn (Trt)-Phe-HMP Linker bha resins
Embodiment 6：The synthesis of Teriparatide peptide resin
The Fmoc-Phe-HMP Linker MBHA resins (substitution value 0.50mmol/g) of 0.1mol embodiments 3 are taken, are used
20%PIP/DMF solution deprotects 25 minutes, and washing filtering obtains the H-Phe-HMP Linker Amide resins of Fmoc.
0.3mol Fmoc-Asn (Trt) and 0.3mol HOBt are taken, are dissolved with appropriate DMF；0.3mol DIC separately are taken, are stirred
Under be slowly added into, continue to be stirred to react 30 minutes, be added in above-mentioned H-Phe-HMP Linker MBHA resins, coupling reaction
120~300 minutes, reaction end was subject to ninhydrin method and is detected, washing filtering, then with 20%PIP/DMF solution deprotection 25
Minute, washing filtering obtains Asn (Trt)-Phe-HMP Linker MBHA resins.
Ibid method is sequentially ingressed into following table protected amino acid or segment, obtains Teriparatide peptide resin：
H-Ser(tBu)-Val-Ser(tBu)-Glu(OtBu)-Ile-Gln(Trt)-Leu-Met-His(Trt)-Asn
(Trt)-Leu-Gly-Lys(Boc)-His(Trt)-Leu-Asn(Trt)-Ser(tBu)-Met-Glu(OtBu)-Arg(Pbf)-
Val-Glu(OtBu)-Trp(Boc)-Leu-Arg(Pbf)-Lys(Boc)-Lys(Boc)-Leu-Gln(Trt)-Asp(OtBu)-
Val-His (Trt)-Asn (Trt)-Phe-HMP Linker MBHA resins
Embodiment 7：The preparation of Teriparatide crude product
Teriparatide peptide resin made from 0.05mol embodiments 4 is taken, TFA, volume hundred that percent by volume is 90% is added
Divide the EDT that ratio is 5%, the mixing acid hydrolysis solution acidolysis (the vertical pa peptide resin of mixing acid hydrolysis solution 10mL/ cuts) that surplus is water composition, stirs
It mixes uniformly, reaction 3 hours is stirred at room temperature, reaction mixture is filtered using sand core funnel, collects filtrate, resin is again with a small amount of TFA
Washing 3 times, be concentrated under reduced pressure after merging filtrate, be added anhydrous ether precipitation, then with anhydrous ether wash precipitation 3 times, drain class is white
Color powder is Teriparatide crude product, and crude product purity is 85.7%.
Embodiment 8：The preparation of Teriparatide crude product
Teriparatide peptide resin made from 0.05mol embodiments 5 is taken, TFA, volume hundred that percent by volume is 85% is added
Divide the EDT that ratio is 7.5%, the mixing acid hydrolysis solution acidolysis (the vertical pa peptide resin of mixing acid hydrolysis solution 15mL/ cuts) that surplus is water composition,
It stirs evenly, reaction 3 hours is stirred at room temperature, reaction mixture is filtered using sand core funnel, collects filtrate, and resin is used a small amount of again
TFA is washed 3 times, is concentrated under reduced pressure after merging filtrate, anhydrous ether precipitation is added, then wash precipitation 3 times with anhydrous ether, is drained to obtain class
White powder is Teriparatide crude product, and crude product purity is 86.9%.
Embodiment 9：The preparation of Teriparatide crude product
Teriparatide peptide resin made from 0.05mol embodiments 6 is taken, TFA, volume hundred that percent by volume is 85% is added
Divide the EDT that ratio is 7.5%, the mixing acid hydrolysis solution acidolysis (the vertical pa peptide resin of mixing acid hydrolysis solution 15mL/ cuts) that surplus is water composition,
It stirs evenly, reaction 3 hours is stirred at room temperature, reaction mixture is filtered using sand core funnel, collects filtrate, and resin is used a small amount of again
TFA is washed 3 times, is concentrated under reduced pressure after merging filtrate, anhydrous ether precipitation is added, then wash precipitation 3 times with anhydrous ether, is drained to obtain class
White powder is Teriparatide crude product, and crude product purity is 87.7%.
Embodiment 10：Teriparatide purifying crude
7 gained Teriparatide crude product of Example adds water stirring and dissolving, 0.45 μm of filtering with microporous membrane of solution, purifying
It is spare；
It is purified using high performance liquid chromatography, the reverse phase C18 that purifying chromatograph packing material is 10 μm, flow phase system is
The column flow rate of 0.1%TFA/ aqueous solution -0.1%TFA/ acetonitrile solutions, 77mm*250mm is 90mL/min, using gradient system
System elution, cycle sample introduction purifying, takes crude product solution to be splined in chromatographic column, starts mobile phase elution, collects main peak and boils off acetonitrile
Afterwards, Teriparatide purifying intermediate concentrate is obtained；
It takes Teriparatide to purify intermediate concentrate, is filtered with 0.45 μm of filter membrane spare；
It carries out changing salt using high performance liquid chromatography, flow phase system is 1% acetic acid/water solution-acetonitrile, purifying chromatography
The column flow rate for the reverse phase C18,77mm*250mm that filler is 10 μm is 90mL/min, using gradient elution, sample prescription in cycle
Method is splined in chromatographic column, is started mobile phase elution, is acquired collection of illustrative plates, observe the variation of trap, and collection changes salt main peak and with dividing
It analyses liquid phase and detects purity, salt main peak solution is changed in merging, is concentrated under reduced pressure, obtains Teriparatide aqueous acetic acid, is freeze-dried, obtains special
Vertical pa peptide sterling 98.8g, total recovery 47.3%, molecular weight：4178.8 (100%M+H), purity：99.4%, it is maximum single miscellaneous
Matter 0.11%.
Embodiment 11：Teriparatide purifying crude
8 gained Teriparatide crude product of Example adds water stirring and dissolving, 0.45 μm of filtering with microporous membrane of solution, purifying
It is spare；
It is purified using high performance liquid chromatography, the reverse phase C18 that purifying chromatograph packing material is 10 μm, flow phase system is
The column flow rate of 0.1%TFA/ aqueous solution -0.1%TFA/ acetonitrile solutions, 77mm*250mm is 90mL/min, using gradient system
System elution, cycle sample introduction purifying, takes crude product solution to be splined in chromatographic column, starts mobile phase elution, collects main peak and boils off acetonitrile
Afterwards, Teriparatide purifying intermediate concentrate is obtained；
It takes Teriparatide to purify intermediate concentrate, is filtered with 0.45 μm of filter membrane spare；
It carries out changing salt using high performance liquid chromatography, flow phase system is 1% acetic acid/water solution-acetonitrile, purifying chromatography
The column flow rate for the reverse phase C18,77mm*250mm that filler is 10 μm is 90mL/min, using gradient elution, sample prescription in cycle
Method is splined in chromatographic column, is started mobile phase elution, is acquired collection of illustrative plates, observe the variation of trap, and collection changes salt main peak and with dividing
It analyses liquid phase and detects purity, salt main peak solution is changed in merging, is concentrated under reduced pressure, obtains Teriparatide aqueous acetic acid, is freeze-dried, obtains special
Vertical pa peptide sterling 102.7g, total recovery 49.2%, molecular weight：4178.6 (100%M+H), purity：99.5%, it is maximum single
Impurity 0.10%.
Embodiment 12：Teriparatide purifying crude
9 gained Teriparatide crude product of Example adds water stirring and dissolving, 0.45 μm of filtering with microporous membrane of solution, purifying
It is spare；
It is purified using high performance liquid chromatography, the reverse phase C18 that purifying chromatograph packing material is 10 μm, flow phase system is
The column flow rate of 0.1%TFA/ aqueous solution -0.1%TFA/ acetonitrile solutions, 77mm*250mm is 90mL/min, using gradient system
System elution, cycle sample introduction purifying, takes crude product solution to be splined in chromatographic column, starts mobile phase elution, collects main peak and boils off acetonitrile
Afterwards, Teriparatide purifying intermediate concentrate is obtained；
It takes Teriparatide to purify intermediate concentrate, is filtered with 0.45 μm of filter membrane spare；
It carries out changing salt using high performance liquid chromatography, flow phase system is 1% acetic acid/water solution-acetonitrile, purifying chromatography
The column flow rate for the reverse phase C18,77mm*250mm that filler is 10 μm is 90mL/min, using gradient elution, sample prescription in cycle
Method is splined in chromatographic column, is started mobile phase elution, is acquired collection of illustrative plates, observe the variation of trap, and collection changes salt main peak and with dividing
It analyses liquid phase and detects purity, salt main peak solution is changed in merging, is concentrated under reduced pressure, obtains Teriparatide aqueous acetic acid, is freeze-dried, obtains special
Vertical pa peptide sterling 101.3g, total recovery 48.5%, molecular weight：4178.6 (100%M+H), purity：99.1%, it is maximum single
Impurity 0.13%.
The above is only a preferred embodiment of the present invention, it is noted that for the ordinary skill people of the art
For member, various improvements and modifications may be made without departing from the principle of the present invention, these improvements and modifications are also answered
It is considered as protection scope of the present invention.
Claims (8)
1. a kind of method of synthesis Teriparatide, which is characterized in that include the following steps：
Step 1, N-terminal coupling have the Phe of protecting group to be carried out with HMP Linker resins under coupling reagent and activating reagent effect
Esterification, obtains peptide resin 1, and the HMP Linker resins are HMP Linker Amide resins, HMP Linker BHA
Resin or HMP Linker MBHA resins；
Step 2, according to the sequence of Teriparatide amino acid sequence C-terminal to N-terminal, from peptide resin 1, in condensation reagent and activation
Under reagent effect, remaining protected amino acid is carried out to extend coupling one by one, corresponding peptide resin is obtained after extending coupling every time,
Final to obtain Teriparatide resin, then acidolysis obtains Teriparatide crude product, and Teriparatide purifying crude turns acetate and obtains spy
Vertical pa peptide sterling；
EDT that it is 1-10% for the TFA of 80-95%, percent by volume by percent by volume that the acidolysis, which is used, surplus are water group
At mixing acid hydrolysis solution acidolysis.
2. method according to claim 1, which is characterized in that the N-terminal coupling has Phe the and HMP Linker trees of protecting group
The molar ratio of fat is 1-6:1.
3. method according to claim 1, which is characterized in that extend the protected amino acid and corresponding peptide tree when coupling every time
The molar ratio of fat is 1-6:1.
4. method according to claim 1, which is characterized in that the condensation reagent be N, N- diisopropylcarbodiimide, N,
N- dicyclohexylcarbodiimides, hexafluorophosphoric acid benzotriazole -1- bases-oxygroup tripyrrole alkyl phosphorus/organic base, 2- (7- azepines -
1H- benzotriazole -1- bases) -1,1,3,3- tetramethylureas hexafluorophosphoric acid ester/organic base, benzotriazole-N, N, N', N'- tetra-
In methylurea hexafluorophosphate/organic base, O- benzotriazole-N, N, N', N'- tetramethylurea tetrafluoro boric acid ester/organic base
It is a kind of.
5. method according to claim 4, which is characterized in that the organic base be n,N-diisopropylethylamine, triethylamine or
N- methylmorpholines.
6. method according to claim 1, which is characterized in that the activating reagent is I-hydroxybenzotriazole or N- hydroxyls-
7- azepine benzotriazole.
7. method according to claim 1, which is characterized in that the coupling reagent is N, N- diisopropylcarbodiimide/4-
Dimethylamino naphthyridine Dual system coupling reagent.
8. method according to claim 1, which is characterized in that the purifying turns acetate step and is：
Teriparatide crude product adds 10% acetum to dissolve, 0.45 μm of filtering with microporous membrane of solution, and purifying is spare；
It is purified using high performance liquid chromatography, the reverse phase C18 that purifying chromatograph packing material is 10 μm, flow phase system is
The column flow rate of 0.1%TFA/ aqueous solution -0.1%TFA/ acetonitrile solutions, 77mm*250mm is 90mL/min, using gradient system
System elution, cycle sample introduction purifying, takes crude product solution to be splined in chromatographic column, starts mobile phase elution, collects main peak and boils off acetonitrile
Afterwards, Teriparatide purifying intermediate concentrate is obtained；
It takes Teriparatide to purify intermediate concentrate, is filtered with 0.45 μm of filter membrane spare；
It carries out changing salt using high performance liquid chromatography, flow phase system is 1% acetic acid/water solution-acetonitrile, purifying chromatograph packing material
Column flow rate for 10 μm of reverse phase C18,77mm*250mm is 90mL/min, using gradient elution, quadrat method in cycle, on
Sample starts mobile phase elution, acquires collection of illustrative plates, observe the variation of trap in chromatographic column, and collection changes salt main peak and with analyzing liquid
Salt main peak solution is changed in mutually detection purity, merging, is concentrated under reduced pressure, obtains Teriparatide aqueous acetic acid, is freeze-dried, get Te Lipa
Peptide sterling.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510295556.2A CN104910269B (en) | 2015-06-02 | 2015-06-02 | A method of synthesis Teriparatide |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510295556.2A CN104910269B (en) | 2015-06-02 | 2015-06-02 | A method of synthesis Teriparatide |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN104910269A CN104910269A (en) | 2015-09-16 |
| CN104910269B true CN104910269B (en) | 2018-08-17 |
Family
ID=54079755
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201510295556.2A Active CN104910269B (en) | 2015-06-02 | 2015-06-02 | A method of synthesis Teriparatide |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN104910269B (en) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105384809B (en) * | 2015-12-30 | 2019-05-14 | 济南康和医药科技有限公司 | A kind of method that segment method solid-liquid combination prepares Teriparatide |
| CN109096388A (en) * | 2017-07-24 | 2018-12-28 | 江苏金斯瑞生物科技有限公司 | A kind of preparation method of Teriparatide |
| CN110642936B (en) * | 2018-06-26 | 2023-01-17 | 深圳翰宇药业股份有限公司 | Method for preparing teriparatide |
| CN111057139B (en) * | 2018-10-17 | 2023-12-22 | 南京华威医药科技集团有限公司 | Novel process for preparing teriparatide |
| CN109897099A (en) * | 2019-03-27 | 2019-06-18 | 哈尔滨吉象隆生物技术有限公司 | A kind of preparation method of Teriparatide |
| CN109879955A (en) * | 2019-03-27 | 2019-06-14 | 哈尔滨吉象隆生物技术有限公司 | A kind of preparation method of Teriparatide |
| CN111848778B (en) * | 2019-04-30 | 2024-03-19 | 上海医药工业研究院 | Teriparatide analogues |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1999031137A1 (en) * | 1997-12-18 | 1999-06-24 | Eli Lilly And Company | Crystalline teriparatide |
| CN102875648A (en) * | 2012-09-26 | 2013-01-16 | 深圳翰宇药业股份有限公司 | Method for preparing telaprevir |
| CN104017064A (en) * | 2014-06-13 | 2014-09-03 | 杭州诺泰制药技术有限公司 | Method for preparing teriparatide |
| CN104530218A (en) * | 2015-01-07 | 2015-04-22 | 哈尔滨吉象隆生物技术有限公司 | Solid-phase synthesis method of teriparatide |
-
2015
- 2015-06-02 CN CN201510295556.2A patent/CN104910269B/en active Active
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1999031137A1 (en) * | 1997-12-18 | 1999-06-24 | Eli Lilly And Company | Crystalline teriparatide |
| CN102875648A (en) * | 2012-09-26 | 2013-01-16 | 深圳翰宇药业股份有限公司 | Method for preparing telaprevir |
| CN104017064A (en) * | 2014-06-13 | 2014-09-03 | 杭州诺泰制药技术有限公司 | Method for preparing teriparatide |
| CN104530218A (en) * | 2015-01-07 | 2015-04-22 | 哈尔滨吉象隆生物技术有限公司 | Solid-phase synthesis method of teriparatide |
Non-Patent Citations (2)
| Title |
|---|
| Improving the Performance of an Acid-labile;CHINH T. BUI，et al.;《Journal of Peptide Science》;20001031;第6卷(第10期);第534页全部以及图1 * |
| 在固相有机合成中应用的含羟基的聚合物载体;李茜等;《离子交换与吸附》;20020531;第18卷(第5期);第469-480页 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN104910269A (en) | 2015-09-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN104910269B (en) | A method of synthesis Teriparatide | |
| CN102875665B (en) | Method for synthesizing liraglutide | |
| CN103497245B (en) | Method for synthesizing thymalfasin | |
| CN106146648B (en) | Synthetic method of parathyroid hormone analogue | |
| DK2421887T3 (en) | A process for the preparation of degarelix | |
| CN109311961A (en) | A kind of synthetic method of Suo Malu peptide | |
| CN104004083B (en) | A kind of method synthesizing Arg34Lys26-(N-EPSILON-(N-ALPHA-Palmitoyl-L-GAMMA-glutamyl))-GLP-1[7-37] | |
| EP3398957B1 (en) | Method for synthesizing etelcalcetide | |
| CN106699871A (en) | Preparation method of liraglutide | |
| CN106928313A (en) | A kind of synthetic method of the terminal modified peptides of C- | |
| CN104177478B (en) | A kind of method for synthesizing Ac-D-2Nal-D-4Cpa-D-3Pal-Ser-4Aph(Hor)-D-4Aph(Cbm)-Leu-Lys(iPr)-Pro-D-Ala-NH2 | |
| CN105524143B (en) | A method of synthesis Ac-D-2Nal-D-4Cpa-D-3Pal-Ser-4Aph(Hor)-D-4Aph(Cbm)-Leu-Lys(iPr)-Pro-D-Ala-NH2 | |
| CN104447962B (en) | A method of synthesis parritide | |
| CN104672320B (en) | A kind of method of pure synthesis in solid state acetic acid redfish calcitonin | |
| CN111087462B (en) | Solid-phase synthesis method of abamectin | |
| CN104844706B (en) | A method of synthesis lixisenatide | |
| CN104844693B (en) | A method of synthesis Linaclotide | |
| CN104817638B (en) | A method of synthesis is for degree Shandong peptide | |
| CN110054662B (en) | Solid-phase synthesis method of Etelcalcetide | |
| CN104177491B (en) | A kind of preparation method of Tesamorelin | |
| CN112679602A (en) | Solid-phase synthesis method of Somaloutide | |
| CN113754753A (en) | Synthetic method of somaglutide | |
| CN109306366B (en) | Method for synthesizing PT141 | |
| CN107778351B (en) | Method for synthesizing octreotide by all-solid-phase method | |
| CN103159850B (en) | Preparation method of tetracosactide |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant | ||
| PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: A method for synthesizing tripeptide Granted publication date: 20180817 Pledgee: Chengdu SME financing Company Limited by Guarantee Pledgor: Chengdu Shengnuo BioTec Co.,Ltd. Registration number: Y2024990000180 |